



## Regulatory Announcement

[Go to market news section](#)

Free annual report  

**Company** Cobra Bio-Manufacturing PLC  
**TIDM** CBF  
**Headline** Agreement Update  
**Released** 07:00 18-May-07  
**Number** 8313W



RNS Number:8313W  
 Cobra Bio-Manufacturing PLC  
 18 May 2007

For Immediate Release

18 May 2007

Cobra Biomanufacturing Update on Manufacturing Agreement with  
 GlaxoSmithKline and the International AIDS Vaccine Initiative

Cobra Biomanufacturing Plc (AIM:CBF) announced on 2 May 2006 that it had signed an agreement with GlaxoSmithKline Biologicals S.A. (GSK Biologicals) and the International AIDS Vaccine Initiative (IAVI), for process development and manufacture of two HIV vaccine candidates for evaluation in clinical trials.

Cobra has successfully completed over 50% of the tasks specified under the agreement with the major part of the outstanding work scheduled for the current financial year. However following a GSK internal project review GSK Biologicals and IAVI have informed Cobra that they have decided to discontinue any further outstanding work with Cobra.

The decision is unrelated to the capabilities or the work undertaken by Cobra; all of Cobra's commitments in this respect having been successfully achieved.

For further information, please contact:

Cobra Biomanufacturing Plc Tel: +44 (0) 1782 714 181  
 David Thatcher, Chief Executive

Buchanan Communications Tel: +44 (0) 207 466 5000  
 Tim Anderson/Mark Court/Rebecca Skye Dietrich

Northbank Communications Tel: +44 (0) 203 008 7555  
 Gemma Bradley/ Kathryn Robertson/Peter Colley

About Cobra

Cobra Biomanufacturing Plc is a leading international manufacturer of biopharmaceuticals to the lifescience industry. Founded in 1992, Cobra provides innovative manufacturing solutions to the biopharmaceutical industry covering DNA, virus, cellular therapeutics and recombinant protein products. Cobra was the first company to develop GMP (Good Manufacturing Practice) standard DNA manufacture in Europe, with specific expertise in DNA medicines.

A range of unique, patented technologies, underpins this revenue generating business.

Cobra floated on the Alternative Investment Market of the London Stock Exchange in June 2002 raising £7 million and raised a further £5.2 million in May 2003 in order to further expand capacity in Oxford UK.

[www.cobrabiio.com](http://www.cobrabiio.com)

This information is provided by RNS  
The company news service from the London Stock Exchange

END

Close

**London Stock Exchange plc is not responsible for and does not check content on this Website. Website users are responsible for checking content. Any news item (including any prospectus) which is addressed solely to the persons and countries specified therein should not be relied upon other than by such persons and/or outside the specified countries. [Terms and conditions](#), including restrictions on use and distribution apply.**

©2007 London Stock Exchange plc. All rights reserved